

PHARMACOVIGILANCE FOR ADVERSE DRUG REACTIONS IN PATIENTS ON NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND HEPATIC DYSFUNCTION IN ACECLOFENAC THERAPY IN SOUTH DELHI HOSPITAL

NIYAZ ALAM^{a*}, RAJEEV KUMAR^b, ALOK BHARDWAJ^b

^aDepartment of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India, ^bDepartment of Pharmacology, Rameesh Institute of Vocational & Technical Education, Kasna Road, Greater Noida, Gautambudh Nagar, 210306, India.
Email: niyazpharma@yahoo.co.in

Received: 24 Apr 2012, Revised and Accepted: 11 Jun 2012

ABSTRACT

Objectives: To carry out Pharmacovigilance for Adverse Drug Reactions in Non-Steroidal anti-inflammatory drugs therapy. And evaluate biochemical changes for hepatic dysfunction in patients using Aceclofenac.

Setting: 300 patients were the subjects in Orthopaedics Department of a Multispecialty Hospital, in South Delhi.

Method: It was a duly approved, pharmacovigilance study, in patients on NSAIDs therapy, conducted by competent professionals. The data was obtained from physicians' prescribing records and patients by individual interviews using the structured proformas as per World Health Organisation guidelines. Hepatic function was evaluated by enzymatic estimations (SGOT, SGPT, γ -GTP).

Keyfindings: In 300 patients, 23 cases of ADRs were reported, showing following demography; 39% males, 61% females, 30% were between 41-50 yrs, 21% between 31-40 yrs. 52% alcoholics, 48% non-alcoholics, 61% smokers, 39% non-smokers, 48% vegetarians, 52% non-vegetarians. ADR cases on combination therapy were 69%, on monotherapy 31%. ADR cases associated with Diclofenac 2.6%, aceclofenac 1%, nimesulide 1.6%, ibuprofen 1.6%, paracetamol 0.6%. On basis of severity of ADRs, 6.6% cases were mild, 1% were moderate. As per Naranjo's scale, 6% were classified as possible and 1.3% were classified probable & unlikely 0.3%. Majority of the patients, although experienced some physical signs of hepatic ADRs, did not have significant change in the biochemical parameters from that of the normal; SGOT 29 ± 1.823^{NS} , SGPT 30.94 ± 1.796^{NS} , γ GTP 19.21 ± 1.806^{NS} .

Conclusion: The pharmacovigilance study demonstrated that the incidence of ADRs was found to be higher in elderly patients (> 40 yrs), in females, alcoholics, smokers, non-vegetarians. Most of the adverse effects were mild and tolerable. ADRs were higher with Combination against monotherapy; diclofenac was associated most with ADRs followed by nimesulide, ibuprofen, aceclofenac and paracetamol.

Aceclofenac did not produce hepatic dysfunction during the period of therapy.

Keywords: Pharmacovigilance, ADR, NSAIDs, Compliance, SGOT, SGPT, γ -GTP.

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs having; analgesic, antipyretic and anti-inflammatory effects.¹ NSAIDs act by interfering with the production of prostaglandins by inhibiting the enzyme Cyclo-oxygenase (COX), both COX-1 and COX-2, reducing inflammation but at the same time blocking the protective role of COX-1, thus producing adverse effects, particularly on the gastric mucosa. NSAIDs COX-2 inhibitors are thought to act by selectivity blocking COX-2, thereby reducing pain and inflammation, but not blocking COX-1.

NSAIDs are associated with certain adverse drug reactions such as; allergic reactions, skin reactions, gastrointestinal effects, renal complications, alteration of hepatic enzyme levels and rarely hepatopathies.² These effects are dose-dependent, and in many cases severe enough to pose the risk of ulcer perforation, upper gastrointestinal bleeding, and death, limiting the use of NSAID therapy. Many of these events are avoidable; a review of physician visits and prescriptions estimated that unnecessary prescriptions for NSAIDs were written in 42% of visits.³

A prospective trail for hepatotoxicity, with 7,000 patients taking NSAIDs reported that, 3% had persistent abnormalities (elevations) on more than one liver function test. Abnormalities in liver function are almost always reversible with the cessation of NSAIDs.⁴ Toxic hepatic reactions usually occur within three months. Some NSAIDs (Benoxaprofen, fenclofenac, Ibufernac, Bendazac, pirofen) have been withdrawn from the market in the early 1980s because of fatal hepatotoxicity.⁵ Nimesulide was withdrawn in 2002 because of a high frequency of hepatotoxicity.⁶

Aceclofenac is a well tolerated, potent NSAID, effective orally, at a dose of 100 mg b.i.d. Withdrawal rate for Aceclofenac due to gastrointestinal adverse effects is lower than Ketoprofen and Tenoxicam.⁷ Aceclofenac is an effective analgesic and anti-inflammatory agent with a good tolerability profile. It has proved as effective as diclofenac, naproxen and piroxicam in patients with osteoarthritis.⁸

WHO defines 'adverse drug reaction' (ADR) as any response to a drug which is noxious and unintended and occurs at doses normally used in human for prophylaxis, diagnosis or therapy of disease or the modification of physiological function'. This definition excludes therapeutic failures, intentional and accidental poisoning and drug abuse.⁹

Management of ADRs adversely affects Pharmacoeconomics of the therapy of disorders.¹⁰ Pharmacovigilance programmes aim at improving patient care and safety, contributing in assessment of benefit, harm, effectiveness and risk of medicines, encouraging their safe, rational and more effective use with appropriate interventions in cases of ADRs.

WHO defines 'Pharmacovigilance' (ADR monitoring) as the science and activities relating to the detection, assessment, understanding and prevention of ADRs or any other medicines related problems (WHO, 2004). The overall purpose of pharmacovigilance is improvement in the safety of medicine. Among the paramedical staff Pharmacists have a more competent place in Pharmacovigilance.¹¹ Pharmacists may interact with patients and report more data on ADRs.¹²

Reports reveal that about 22.3% of the patients experience ADRs.¹³ Also monitoring of ADRs show that of the total visits in medical department, 5.9% are due to drug related events, and 45% due to ADRs.

Current Pharmacovigilance study contains the result of a 4-month observation on monitoring ADRs in patients on NSAIDs therapy in Orthopaedics Department in a Multispecialty Hospital in South Delhi.

MATERIALS AND METHODS

Present Pharmacovigilance study was a duly approved by Jamia Hamdard Institutional Review Board, dated 08th December 2007. It was an open, non-comparative, 4-month study, January to April 2008, conducted at a Multispecialty Teaching Hospital in South Delhi. Suitably qualified and competent professionals were involved in conducting the study. Inclusion criteria - all patients using NSAIDs irrespective of age and sex; and Exclusion criteria - patients mentally retarded, unable to comply, refusing the consent; was observed for

selection of the 300 patients. Informed Consent was signed by the selected patients. The data was obtained from physicians' prescribing records and patients by individual interviews using the proformas for; Informed Consent, ADR monitoring Form, Structured Questionnaire, as per World Health Organisation guidelines¹⁴. Hepatic function was evaluated by enzymatic estimations (SGOT, SGPT, γ -GTP) in blood samples of suspected patients using Aceclofenac therapy.

The evaluation of the probability of ADRs by Naranjo's Scale and by WHO causality Scale has been shown in Table 1 and Table 2 respectively.¹⁵The data were evaluated for statistical significance by applying Students't test.

Table 1: Naranjo's ADR Probability Scale

S. No.	Questions	Yes	No	Do not know	Score
1.	Are there previous conclusive reports on this reaction?	+1	0	0	
2.	Did the adverse event appear after the suspected drug was administered?	+2	-1	0	
3.	Did the adverse event improve when the drug was discontinued or a specific antagonist was administered?	+1	0	0	
4.	Did the adverse reaction reappear when the drug was re-administered?	+2	-1	0	
5.	Are there alternative causes (other than the drug) that could on their own have caused the reaction?	-1	+2	0	
6.	Did the reaction reappear when a placebo was given?	-1	+1	0	
7.	Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?	+1	0	0	
8.	Was the reaction more severe when the dose was increased or less severe when the dose was decreased?	+1	0	0	
9.	Did the patient have the similar reaction to the same or similar drugs in any previous exposure?	+1	0	0	
10.	Was the adverse event confirmed by any objective evidence?	+1	0	0	
					Total Score

Assessment score: Highly probable ≥ 9 ; Probable 5-8; possible 1-4; Unlikely ≤ 0

Table 2: WHO Causality Assessment Scales

Level	Criteria
Certain	<ul style="list-style-type: none"> Event of laboratory abnormality, with plausible time relationship to drug intake Cannot be explained by disease or other drugs Response to withdrawal plausible (pharmacologically, pathologically) Event definitive pharmacologically or phenomenologically. Rechallenge (if necessary)
Probable	<ul style="list-style-type: none"> Event of laboratory abnormality, with reasonable time relationship during intake Unlikely to be attributed to disease or other drugs Response to withdrawal clinically reasonable Rechallenge not necessary
Possible	<ul style="list-style-type: none"> Event or laboratory abnormality, with reasonable time relationship during intake Could also be explained by disease or other drugs Information on drug withdrawal lacking or unclear
Inaccessible/ unclassifiable	<ul style="list-style-type: none"> A report suggesting an adverse reaction Cannot be judged because of insufficient or contradictory information Report cannot be supplemented or verified
Unlikely	<ul style="list-style-type: none"> Event or laboratory abnormality with a time to drug that makes a relationship improbable (but not impossible) Disease or other drugs provide plausible explanations
Conditional /unclassified	<ul style="list-style-type: none"> Event or laboratory test abnormality More data for proper assessment needed or additional data under examination

RESULTS AND DISCUSSION

A total of 23 cases of ADRs were reported in 300 patients. Higher numbers of ADRs cases were between 41-50 yrs and 31-40 yrs, 30% and 21% respectively (Table 3).

On the basis of 23 patients' demographics; a higher percentage of ADRs occurred in females 61% than in males 39%; alcoholics 52%, non-alcoholics 48%, smokers 61%, non-smokers 39%, vegetarians 48%, non-vegetarians 52%. ADR cases in combination therapy were 69% against 31% in monotherapy. ADR cases associated with

Diclofenac 2.6%, aceclofenac 1%, nimesulide 1.6%, Ibuprofen 1.6%, paracetamol 0.6% (Table 4).

As per Naranjo's scale, 6% were classified as possible and 1.3% was classified probable & unlikely 0.3% (Table 5).

Majority of the patients, although experienced some physical signs of hepatic ADRs, did not have significant change in the biochemical parameters from that of the normal; SGOT 29 ± 1.823^{NS} , SGPT 30.94 ± 1.796^{NS} , γ -GTP 19.21 ± 1.806^{NS} (Table 6).

Table 3: ADRs among various age groups in NSAIDs users

Age group	Male	Female	Total (%)
10-20	1	2	3 (13.4%)
21-30	1	2	3 (13.4%)
31-40	2	3	5 (21.7%)
41-50	3	4	7 (30.4%)
51-60	2	3	5 (21.7%)
Grand total	9	14	23

Table 4: ADRs with classes of NSAIDs and with individual drugs

Class	Drugs	Adverse reaction	No. of cases of ADRs		Intervention
			No.	%.	
Aryl acetic acid derivative	Aceclofenac	Dizziness	2		Symtometric treatment Dechallenged
		Diarrhoea	1	13%	
	Diclofenac	Abdominal pain	6	34.87%	Symtometric treatment Symtometric treatment
		Dyspepsia	2		
		<i>Total (drugs class)</i>	<i>11</i>	<i>47.82%</i>	
Propionic acid derivative	Ibuprofen	Epigastric discomfort	3	21.73%	Dose reduced
Preferential COX-2 inhibitor	Nimesulide	Vomiting	2		Symtometric treatment Dechallenged
		Loose motion	5	21.73%	
Para-aminophenol derivative	Paracetamol	Skin rashes	2	8.69%	Dechallenged
Total			23	100%	

On basis of severity of ADRs, 6.6% cases were mild, 1% were moderate.

Table 5: Classification of ADRs according to Naranjo's Scale

Assessment	No. of ADRs	% of ADRs
Unlikely ;<0	01	0.3
Possible ;1-4	18	6
Probable ;5-8	04	1.3
Highly probable;9	0	0
Total	23	7.6

Table 6: Biochemical parameters for hepatic function

	Baseline (mean \pm SEM)	After ^{4th} week (mean \pm SEM)
SGOT	21.316 \pm 1.08	29 \pm 1.823 ^{NS}
SGPT	22.47 \pm 1.519	30.94 \pm 1.796 ^{NS}
GGT	15.42 \pm 1.45	19.21 \pm 1.806 ^{NS}

NS = Non significant when $P > 0.05$

Values after 4th Week are compared with those of baseline.

DISCUSSION

To our knowledge, considering prescription drugs this is the first study providing comprehensive information on the prevalence and the pattern of ADRs in patients using NSAIDs.

A total of 23 cases of ADRs were reported in 300 patients using NSAIDs. Higher numbers of ADRs cases were observed in patients above 40 yrs, females', alcoholics, smokers, non-vegetarians, on combination therapy. Similar observations have been reported in few of the studies.¹⁶ A previous study had already showed that the percentage of ADR was higher in females compared to males.¹⁷

Aryl acetic acid derivatives (Diclofenac, aceclofenac) were the class of NSAIDs, most associated with mild ADRs inclusive of monotherapy and combination therapy. Individually Diclofenac was most associated with ADRs. This is in confirmation with an earlier report.^{18,19}

Most of the ADRs were mild and tolerable, did not require withdrawal of therapy.

As per Naranjo's scale, 6% were classified as possible and 1.3% was classified probable & unlikely 0.3%.

A report reveals that aceclofenac does not affect the liver function adversely.²⁰ Current study also evaluated liver function after four weeks of aceclofenac therapy using γ -GTP as biochemical parameter for the first time in addition to SGOT, SGPT. Majority of the patients using Aceclofenac, although experienced some physical signs of hepatic ADRs, did not have significant change in the biochemical parameters from that of the normal.

CONCLUSION

The prime objective of this study was to monitor ADRs in patients on NSAIDs therapy and improve drug utilization pattern in a hospital setting. Also to measure ADR incidence in various patients

demographics and educate them about life style, diets, alcohol intake, Smoking, etc.

The following are the major findings of this study:

- Care should be exercised while prescribing NSAIDs for long term and in elderly patients as ADR incidents are higher in patients above 40 yrs in age and female.
- Monotherapy with NSAIDs should be preferred to Combination therapy.
- Paracetamol may preferably be prescribed unless others become very essential.
- Aceclofenac may be considered safe in terms of adverse effect on liver.
- The limitation of the present study is the small sample size, and short duration of study.

REFERENCES

1. Rang HP, Dale MM, Ritter JM, Moore PK: Anti-inflammatory and immunosuppressant drug. *Pharmacology* 5th edn. London. Charchill living stone 2003: 244-260.
2. Rains ford KD: Nimesulide- a multifactorial approach to inflammation and pain: scientific and clinical consensus. *Current Medical Research and Opinion* 2006; 22(6):1161-1170.
3. Green JJ, Mandras SM: Pseudoporphyria. *J Am Acad Dermatol* 2001; 44:100-109.
4. Paulus HE: FDA Arthritis Advisory Committe meeting: Liver toxicity of NSAIDs. *Arthritis Rheum* 1982; 25:1124-1125.
5. Castot A, Netter P, Larrey D: Hepatitis aux Anti-inflammatoire Non-steroidiens. Bilan cooperative des centers regionex de pharmacovigilance pour l' Anne 1985. *Therapy* 1988; 43:229-233.
6. Meryse LM, Ana RC, Marie PB, Javier GP, Ana AR, Louis MA et al: Non-steroidal anti-inflammatory drug related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. *Fundamental & clinical Pharmacology* 2006; 20:391-395.
7. Bjordal JM, Ljunngren AE, Kloning A et al: Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trails. *BMJ* 2004; 329:1317.
8. Liane L, Harper S, Simon T, et al. A randomised trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodanal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. *Gastroenterology* 1999; 117:776-83.
9. WHO, Pharmacovigilance: ensuring the safe use of medicines, WHO policy perspective of medicine, Geneva; WHO: 2004.
10. Samuel SA, Rajendra SD, Ebenezzar SE, Jayaharan S, Azir P: Surveillance of Adverse drug reaction at two multidisciplinary hospitals and an outpatients specialty clinic in India. *Int J Pharm Pract* 2002; 10:115-20.
11. Grootheest KV, Olsson S, Couper M, Berg LJ. Pharmacist role in reporting adverse reaction in an international perspective. *Pharmacoepidemiol Drug Safe* 2004; 13:457-64.
12. Grootheest KV, Berg LJ, Pouijjanbrok EP: Contribution of pharmacist to the reporting of ADR. *Pharmacoepidemiol Drug Safe* 2002; 11:205-10.
13. Parthasarathi G, Nyfort-Hansen K, Nahata MC: Adverse drug reactions. *A text book of clinical pharmacy practice* 1st ed. Chennai: Orient Longman Pvt Ltd; 2004: pp 84-104.
14. Kurakawa T, Correa-Nunes AM, Czarnecki A: Guidelines for setting up and running of pharmacovigilance center. Upsala. Swedon: WHO collaborating Centre for International Drug Monitoring 2000: pp 4-10.
15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al: A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther.* 1981; 30(2): 239-45
16. Irshaid YM, Al-Homrany MA: Pharmacoepidemiological study of prescription pattern of analgesics, antipyretics, and non-steroidal anti-inflammatory drugs at a tertiary health care center. *Saudi Med J.* 2007; 28(3):369-374.
17. Ramesh M, Pandit J and G.Parthasarathi: Adverse drug reactions in a South India hospital their severity and cost involved. *Pharmacology and Drug safety* 2003; 12: 687-692.
18. Shi W, Wang YM, Li SL, Yan M, Chen BY, Li D: Risk factors of adverse drug reaction caused by nimesulide in Shanghais patients with osteoarthropathy. *Drugs Exp Clin Res.* 2003; 29(4):161-168.
19. Sanchez BM, Capriles HA, Caballero FF: NSAID-induced urticaria and angiodema: a reappraisal of its clinical management. *Am J Clin Dermatol.* 2002; 3(9):599-607.
20. Marsicano LJ, Ocampo ME: Hepatic tolerance of aceclofenac. *G E N* 1994; 48(4):250-5.